CEBPB and gastrointestinal stromal tumor: In GIST patients [97, 116] and KitV558Δ/+ mouse GIST model [116], imatinib, through activating CCAT enhancer binding protein β (C/EBPβ) [116], drives intratumoral macrophage M2 polarization and contributes to the development of immunosuppressive microenvironment, which might partially explain the survival of tumor cells during imatinib therapy.